ThyraMIR, a microRNA gene expression classifier for identification of indeterminate benign and malignant thyroid nodules, was recently launched by PDI, Inc., according to a company press release.
Use in combination with ThyGenX, ThyraMIR Interpace Diagnostics’ genetic mutation panel resulted in a negative predictive value of 94% and a positive predictive value of 74%, revealing a cancer prevalence of 32%. The high specificity and sensitivity of ThyraMIR and ThyGenX will allow physicians to identify and rule out thyroid cancer with a single testing regimen.
“A testing regimen that provides both high [negative predictive value] and [positive predictive value] would be highly predictive and significantly improve the physician’s ability to correctly identify indeterminate thyroid nodules as being either benign or malignant,” Alexander Shifrin, MD, of the Jersey Shore Medical Center, said in the release. “This can potentially result in fewer unnecessary surgeries and improve patient management.”
The expression levels of 10 miRNAs are used by ThyraMIR, and ThyGenX identifies mutations and genetic alterations linked to differentiated thyroid cancers. A positive or negative cancer test can result from using fine-needle aspiration procedures identified through the combination of ThyraMIR and ThyGenX.
“We are excited about the launch of ThyraMIR and its combined use with our thyroid oncogene mutational panel, ThyGenX, as they further advance physicians’ ability to correctly diagnose thyroid nodules,” Nancy Lurker, CEO of PDI, Inc., said in the release.